RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.

Cost-utility analysis of treatments for advanced non-small cell lung cancer

Lairson, DR., Parikh, R., Cormier, JN., Wenyaw, C., & Du, XL. (2015). Cost-utility analysis of treatments for advanced non-small cell lung cancer. American Journal of Pharmacy Benefits, 7(6), 271-9. http://www.ajpb.com/journals/ajpb/2015/ajpb_novemberdecember2015/cost-utility-analysis-of-treatments-for-advanced-non-small-cell-lung-cancer

Abstract

Platinum-based chemotherapy may be cost-effective compared with no chemotherapy for the overall elderly population and by age group. However, platinum + targeted therapy was not cost-effective compared with the use of platinum-based therapy alone.

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Recent Publications

Article

Developing capacity in identifying cost-effective interventions to prevent and reduce obesity in China
Article

US consumer and healthcare professional preferences for combination COVID-19 and influenza vaccines
Article

Comparing youth-friendly clinics to the standard of care for adolescent girls and young women in Malawi: A qualitative analysis
Article

Patient-reported outcome improvements following scalp hair regrowth among patients with Alopecia Areata: analysis of the ALLEGRO-2b/3 trial